• Pressemitteilung BoxID 499835

Genentech and Pfizer Share CDx Success Insights at the 4th Molecular Diagnostics for Cancer Drug Development in Boston

(PresseBox) (London, UK, ) The final agenda has been released for the 4th Molecular Diagnostics for Cancer Drug Development meeting (Boston, June 25th - 28th 2012).

The 3 day agenda features 31 expert speakers including the key project leaders of Zelboraf (Genentech) and Xalkori (Pfizer) on overcoming the scientific and commercial hurdles of targeting a drug to a specific patient subpopulation, and how they gained regulatory approval of their companion diagnostics last year.

They join oncology and diagnostics experts representing: Clovis Oncology, MD Anderson Cancer Center, Johnson & Johnson, National Cancer Institute, Astellas Pharma, Fred Hutchinson Cancer Research Center, The Biomarkers Consortium, Novartis, Daiichi-Sankyo, FDA, ImmunoGen, Bristol-Myers Squibb, Morphotek, Eisai, Bayer, Dana-Farber Cancer Institute, AVEO Pharmaceuticals, Celgene and Merck.

Visit the event website or download the brochure to see the full speaker line up and agenda.

Diese Pressemitteilungen könnten Sie auch interessieren

Patientenmerkblatt veröffentlicht: Was antimikrobielles Kupfer für die Gesundheit tun kann

, Medizintechnik, Deutsches Kupferinstitut Berufsverband e.V.

Krankenhäuser in der ganzen Welt versuchen das Problem krankenhausbürtiger Infektionen durch zahlreiche Maßnahmen in den Griff zu bekommen -...

Intensity Matters, Age Does Not!

, Medizintechnik, Hocoma AG

Older patients benefit from high-intensity neurorehabilitation just as much as young patients, proves a recent research paper published in the...

条件付きMRI対応両室ペーシング機能付き植込み型除細動器

, Medizintechnik, BIOTRONIK

バイオトロニックジャパン株式会社(本社:­東京都渋谷区、代表取締役社長:ジェフリー­・アニス)は、この度条件付きMRI対応両­室ペーシング機能付き植込み型除細動器「イ­トレヴィア 7 CRT-D ProMRIシリーズ」のMRI撮像条件を­変更する薬事承認を取得したことを発表しま­した。 近年、条件付きMRI対応の心臓­血管植込み型電子デバイス(CIEDs)は­新規植込み手術において機種選定のゴールド­スタンダードになりつつあります。イトレヴ­ィア...

Disclaimer